Arca
Skip to content

Colorectal cancer

Drug research and approvals for colorectal cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 1,565 studies of colorectal cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 80 drug trials for it since 2013, FDA has 4 approved and 3 open orphan designations naming it, and the EU has 12 authorised medicines for it.

  • Recruiting worldwide: 1,565
  • Trials authorized in Canada: 80
  • FDA orphan approvals: 4
  • EU medicines: 12

Recruiting Now

Newest start dates first, of 1,565 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 80; search them all in Canada trials
Aug 19, 2026A phase Ib, multicenter, randomized study evaluating the safety and activity of gdc-7035 with anti-cancer therapies as first-line treatment in patients with…GDC-7035 (RO7782493) / PANITUMUMAB / OXALIPLATIN / IRINOTECAN / GEMCITABINE /…RochePending
Apr 24, 2026A randomized, open label, 3-arm phase 3 study of precemtabart tocentecan with or without bevacizumab compared to trifluridine/tipiracil plus bevacizumab in…PRECEMTABART TOCENTECAN (M9140) / AVASTIN (BEVACIZUMAB) / TIPIRACIL-TRIFLURIDINEMerck KGaAOngoing
Mar 9, 2026A randomized, double blind, phase 3 study of standard-of-care chemotherapy and bevacizumab with or without inca33890 in the first line treatment of metastatic…INCA33890 / LEUCOVORIN / 5-FLUOROURACILIncyte CorporationOngoing
Dec 23, 2025An interventional, phase 3, double-blind, randomized study to evaluate the efficacy and safety of pf-08634404 in combination with chemotherapy versus…PF-08634404 (SSGJ-707) / ZIRABEV / FLUOROURACIL / LEUCOVORIN / OXALIPLATINPfizerOngoing
Dec 12, 2025Rosetta crc-203: a blinded, randomized phase 2/3 study of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in…PUMITAMIG (BMS-986545; BNT327)Bristol-Myers SquibbOngoing
Dec 10, 2025A randomized, active-controlled, double-blind, multicenter, phase 3 clinical folfox versus bevacizumab in combination with folfox for the first-line study…IVONESCIMABSUMMIT THERAPEUTICS INC.Ongoing
Nov 25, 2025A phase II, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of inavolisib with bevacizumab plus folfox or…INAVOLISIB (RO7113755) / BEVACIZUMAB / 5-FLUOROURACIL / IRINOTECAN / FOLINIC…RocheClosed
Aug 29, 2025A phase 3, randomized, open-label, multicenter clinical study to evaluate the safety and efficacy of mk-1084, cetuximab, and mfolfox6 versus mfolfox6 with or…MK-1084 / CETUXIMABMerck & Co. (MSD)Ongoing
May 27, 2025A randomized, open label, multicenter, phase 2 study to evaluate the safety and efficacy of two dose levels of ono-4578 with opdivo® in combination with…ONO-4578 (BMS-986310) / OPDIVO (NIVOLUMAB) / ZIRABEV (BEVACIZUMAB) / LEUCOVORIN…Ono PharmaceuticalOngoing
Mar 28, 2025Safely optimizing body weight with mifomelatide (tcmcb07) in patients with newly diagnosed colorectal cancer (crc) or pancreatic ductal adenocarcinoma (pdac)…MIFOMELATIDE (TCMCB07)ENDEVICA BIOOngoing

FDA Orphan Designations

Approved first, then open designations, newest first
Jan 16, 2025Lumakrasin combination with panitumumab, for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as…Amgen Inc.Approved
Jan 19, 2023Tukysain combination with trastuzumab for the treatment of adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal…Seagen Inc.Approved
Apr 29, 2011FusilevFor use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancerAcrotech Biopharma LLCApproved
Dec 12, 1991Leucovorin calciumFor use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.Immunex CorporationApproved
Jul 22, 2025small molecule that selectively and irreversibly inhibits…treatment of colorectal cancer (CRC) harboring KRAS p.G12C mutant proteinD3 Bio (Wuxi) Co., LtdDesignated
Feb 22, 2024autologous logic-gated Tmod chimeric antigen receptor (CAR)…Treatment of germline heterozygous HLA-A*02(+) patients with colorectal cancer that expresses CEA and has lost HLA A*02 expressionA2 Biotherapeutics, Inc.Designated
Jun 23, 1988Leucovorin calciumFor use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.Glaxo Wellcome Research and DevelopmentDesignated

Medicines Authorised in the EU

Newest first
Jun 20, 2024FruzaqlafruquintinibTakeda Pharmaceuticals International AG IrelandEMA ↗
Sep 19, 2018BraftoviencorafenibPierre Fabre MedicamentEMA ↗
Apr 25, 2016Lonsurftrifluridine;tipiracilLes Laboratoires ServierEMA ↗
Aug 26, 2013StivargaregorafenibBayer Pharma AGEMA ↗
Feb 1, 2013ZaltrapafliberceptSanofi Winthrop IndustrieEMA ↗
Nov 19, 2012Capecitabine Medaccapecitabine · genericmedac Gesellschaft für klinische Spezialpräparate mbHEMA ↗
Apr 20, 2012Capecitabine Tevacapecitabine · genericTeva Pharma B.V.EMA ↗
Apr 20, 2012Ecansya (previously Capecitabine Krka)capecitabine · genericKRKA tovarna zdravil d.d. Novo mestoEMA ↗
Apr 20, 2012Capecitabine Accordcapecitabine · genericAccord Healthcare S.L.U.EMA ↗
Dec 3, 2007VectibixpanitumumabAmgen Europe B.V.EMA ↗
Jun 29, 2004ErbituxcetuximabMerck Europe B.V.EMA ↗
Feb 2, 2001XelodacapecitabineCHEPLAPHARM Arzneimittel GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.